HALISTER: Teva Wins U.S. Approval to Buy Actavis After Selling Generics

Teva Wins U.S. Approval to Buy Actavis After Selling Generics

(Bloomberg) -- Teva Pharmaceutical agreed to sell rights and assets related to 79 products to settle FTC claims that proposed acquisition of Allergan’s generic business would be anticompetitive.
  • Remedy requires Teva to divest drug portfolio to 11 rival firms
  • Marks largest drug divestiture order in an FTC pharmaceutical merger case
Statement: Link
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
TEVA IT (Teva Pharmaceutical Industries Ltd)
AGN US (Allergan plc)

To de-activate this alert, click here

UUID: 7947283